205309-81-5

205309-81-5 structure

Name: DL-TBOA
Chemical Name: (3R)-3-(Benzyloxy)-D-aspartic acid-(3S)-3-(benzyloxy)-L-aspartic acid (1:1)
CAS Number: 205309-81-5
Molecular Formula: C₁₁H₁₃NO₅
Molecular Weight: 478.449
Catalog: Signaling Pathways Membrane Transporter/Ion Channel EAAT2
Create Date: 2018-07-18 20:44:38
Modify Date: 2025-08-25 10:46:40
DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively[1][2][3].

Name	(3R)-3-(Benzyloxy)-D-aspartic acid-(3S)-3-(benzyloxy)-L-aspartic acid (1:1)
Synonyms	D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-, compd. with L-aspartic acid, 3-(phenylmethoxy)-, (3S)- (1:1) (3R)-3-(Benzyloxy)-D-aspartic acid - (3S)-3-(benzyloxy)-L-aspartic acid (1:1)

Description	DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively[1][2][3].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> EAAT2
Target	IC50: 70 μM (EAAT1), 6 μM (EAAT2) and 6 μM (EAAT3); Ki: 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4) and 3.2 μM (EAAT5)[1][2][3]
In Vitro	DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability[4]. DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin[4]. Cell Viability Assay[4] Cell Line: HCT116 and LoVo cell lines Concentration: 70 μM or 350 μM Incubation Time: 48 hours Result: Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. Cell Viability Assay[4] Cell Line: HCT116 and LoVo cell lines Concentration: 350 μM Incubation Time: 24 hours Result: p53 induction by SN38 and oxaliplatin was decreased.
References	[1]. Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201. [2]. Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8. [3]. Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302. [4]. Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.

Molecular Formula	C₁₁H₁₃NO₅
Molecular Weight	478.449
Exact Mass	478.158752

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

205309-81-5	2093503-71-8
871123-98-7	73952-11-1
1420043-66-8	7200-25-1
116797-51-4	78966-69-5
6027-13-0	18760-80-0
2325274-34-6	2380169-87-7
61461-40-3	2380169-22-0
2380097-29-8	2380086-69-9
2380098-73-5	2380143-80-4
2380061-96-9	2380077-56-3